The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | Stereotactic ablative radiotherapy (SABR) for lung cancer treatment
Stephanie Kroeze, MD, PhD , University Hospital of Zürich (Universitätsspital Zürich), Zurich, Switzerland, discusses the use of stereotactic ablative radiotherapy (SABR) in lung cancer. SABR is particularly used to treat stage I lung cancer but can be also used for metastases at very high doses and focally, so that it treats the tumor whilst sparing the surrounding tissue. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
